Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

757 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regional variability in Canadian routine care of type 2 diabetes, hypercholesterolemia, and hypertension: Results from the The Cardio-Vascular and metabolic treatments in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry.
Goldenberg R, Bell A, Cheng W, Paron E, Fils-Aimé N, Burrows M, Blavignac J, Barakat M. Goldenberg R, et al. Among authors: barakat m. J Cardiol. 2020 Oct;76(4):385-394. doi: 10.1016/j.jjcc.2020.04.008. Epub 2020 May 27. J Cardiol. 2020. PMID: 32473770 Free article.
Real-world effectiveness of treatments for type 2 diabetes, hypercholesterolemia, and hypertension in Canadian routine care - Results from the CardioVascular and metabolic treatment in Canada: Assessment of REal-life therapeutic value (CV-CARE) registry, 12-months results.
Goldenberg R, Bell A, Cheng W, Fils-Aimé N, Burrows M, Blavignac J, Parron E, Barakat M. Goldenberg R, et al. Among authors: barakat m. Diabetes Res Clin Pract. 2020 Dec;170:108416. doi: 10.1016/j.diabres.2020.108416. Epub 2020 Sep 4. Diabetes Res Clin Pract. 2020. PMID: 32891688
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
Wharton S, Yin P, Burrows M, Gould E, Blavignac J, Christensen RAG, Kamran E, Camacho F, Barakat M. Wharton S, et al. Among authors: barakat m. Int J Obes (Lond). 2021 Aug;45(8):1687-1695. doi: 10.1038/s41366-021-00831-4. Epub 2021 Jun 3. Int J Obes (Lond). 2021. PMID: 34083744 Free PMC article.
757 results